Adjuvant chemotherapy of non-small-cell lung cancer

Por Douillard, J.Y.
Publicado em 2013

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

Por Douillard, J-Y, Ostoros, G, Cobo, M, Ciuleanu, T, McCormack, R, Webster, A, Milenkova, T
Publicado em 2014

PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer recei...

Por Rivera, F., Karthaus, M., Valladares-Ayerbes, M., Gallego, J., Koukakis, R., Demonty, G., Douillard, J.-Y.
Publicado no Ann Oncol (2016)

PD-026 Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective ana...

Por Köhne, C.-H., Rivera, F., Taieb, J., Siena, S., Peeters, M., Koukakis, R., Demonty, G., Douillard, J.-Y.
Publicado no Ann Oncol (2016)

PD-028 Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with s...

Por Peeters, M., Siena, S., Douillard, J.-Y., Rivera, F., Taieb, J., Koukakis, R., Demonty, G., Köhne, C.-H.
Publicado no Ann Oncol (2016)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

Por Bennett, L, Zhao, Z, Barber, B, Zhou, X, Peeters, M, Zhang, J, Xu, F, Wiezorek, J, Douillard, J-Y
Publicado em 2011

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

Por Douillard, J Y, Lerouge, D, Monnier, A, Bennouna, J, Haller, A M, Sun, X S, Assouline, D, Grau, B, Rivière, A
Publicado em 2001

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

Por Cunningham, D, Wong, R P W, D'Haens, G, Douillard, J-Y, Robertson, J, Stone, A M, Van Cutsem, E
Publicado em 2013

P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective po...

Por Sobrero, A., Douillard, J.-Y., Rivera, F., Forget, F., Karthaus, M., Valladares-Ayerbes, M., Demonty, G., Guan, X., Peeters, M.
Publicado no Ann Oncol (2016)

Randomized Phase 3 Study of Panitumumab With FOLFOX4 Compared to FOLFOX4 Alone as 1(st)-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC): The PRIME Trial

Por Douillard, J.Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M.E., Humblet, Y., Cunningham, D., Wolf, M., Gansert, J.
Publicado em 2010

PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma

Por Siena, S., Tabernero, J., Bodoky, G., Cunningham, D., Rivera, F., Ruff, P., Canon, J.-L., Koukakis, R., Demonty, G., Douillard, J.-Y.
Publicado no Ann Oncol (2016)

Selective modification of NMR relaxation time in human colorectal carcinoma by using gadolinium-diethylenetriaminepentaacetic acid conjugated with monoclonal antibody 19-9.

Por Curtet, C, Tellier, C, Bohy, J, Conti, M L, Saccavini, J C, Thedrez, P, Douillard, J Y, Chatal, J F, Koprowski, H
Publicado em 1986

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

Por Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Publicado em 2010

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

Por Pujol, J. L., Monnier, A., Berille, J., Cerrina, M. L., Douillard, J. Y., Rivière, A., Grandgirard, A., Gouva, S., Bizzari, J. P., Le Chevalier, T.
Publicado em 1994

Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

Por Bennouna, J, Breton, J-L, Tourani, J-M, Ottensmeier, C, O'Brien, M, Kosmidis, P, Huat, T E, Pinel, M-C, Colin, C, Douillard, J-Y
Publicado em 2006

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

Por Delord, J-P, Bennouna, J, Artru, P, Perrier, H, Husseini, F, Desseigne, F, François, E, Faroux, R, Smith, D, Piedbois, P, Naman, H, Douillard, J Y, Bugat, R
Publicado em 2007

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

Por Bennouna, J, Perrier, H, Paillot, B, Priou, F, Jacob, J H, Hebbar, M, Bordenave, S, Seitz, J F, Cvitkovic, F, Dorval, E, Malek, K, Tonelli, D, Douillard, J Y
Publicado em 2006

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado em 2007

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado em 2008

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Por Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H. J., Sprumont, D., Zalcberg, J.
Publicado no Ann Oncol (2017)